Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 19, 2018. The document serves as a transaction notification regarding insider trading activities by Persons Discharging Managerial Responsibilities (PDMRs) and persons closely associated with them.
Key Financial Metrics
The filing does not report company-wide financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share acquisition transactions.
| Transaction Date | Instrument | Price per ADS | Total Volume (ADSs) | Exchange |
|---|---|---|---|---|
| January 18, 2018 | GlaxoSmithKline plc ADSs | $38.0676 | 19.625 | New York Stock Exchange |
| January 18, 2018 | GlaxoSmithKline plc ADSs | $38.0676 | 232.515 | New York Stock Exchange |
| January 18, 2018 | GlaxoSmithKline plc ADSs | $38.0676 | 1,826.446 | New York Stock Exchange |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document records routine acquisitions of American Depositary Shares (ADSs) by three executives following the re-investment of dividends paid on January 11, 2018.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory disclosure of specific share transactions.
Key Facts for Investor Verification
- Transaction Nature: All reported transactions were acquisitions of ADSs resulting from dividend re-investment plans, not open market purchases.
- Executives Involved:
- Mr. N. Hirons (SVP, Global Ethics & Compliance): 19.625 ADSs
- Mr. B. McNamara (CEO, Consumer Healthcare): 232.515 ADSs
- Mr. D. E. Troy (SVP & General Counsel): 1,826.446 ADSs
- Transaction Price: All shares were acquired at a uniform price of $38.0676 per ADS.
- Dividend Date: The underlying dividends were paid to shareholders on January 11, 2018.